Progyny COO Cummings Sells 3,437 Shares for $109,000 -- Here's What That Means for Investors

Progyny COO Cummings Sells 3,437 Shares for $109,000 -- Here's What That Means for Investors Josh Kohn-Lindquist, The Motley Fool Sun, July 19, 2026 at 12:01 PM GMT+2 4 min read PGNY Melissa B. Cummings, Chief Operating Officer of Progyny, Inc. (NASDAQ:PGNY), reported a sale of 3,437 shares of common stock on July 14, 2026.

SEC Form 4 filing Transaction summary Metric Value Shares sold 3,437 Transaction value ~$109,056 Post-transaction shares (directly held) 69,934 Post-transaction value $2. 26 million Transaction value based on SEC Form 4 weighted average sale price ($31. 73); post-transaction value based on July 14, 2026, market close ($32.

36). Key questions What were the primary drivers behind this equity disposition? The transaction was structured to address both personal liquidity and tax obligations.

Specifically, 2,244 shares were sold pursuant to a Rule 10b5-1 trading plan established on Dec. 19, 2025, while Progyny withheld 1,193 shares to cover tax liabilities stemming from the vesting of restricted stock units. How does this transaction affect the insider's total exposure to Progyny?

While direct holdings decreased by 5% in this filing, Cummings maintains a significant equity position of 69,934 shares. This remaining stake represents a 0. 0893% ownership interest in the company, valued at $2.

26 million based on the market close on the transaction date. What is the recent context of the stock's performance? Progyny shares were priced at $32.

36 at the close of July 14, 2026, the day the transaction occurred. At that time, the company had delivered a total return of 38% over the preceding 12 months. As of July 15, 2026, market close, the stock was priced at $32.

34. Company Overview Metric Value Share Price (as of market close 2026-07-15) $32. 34 Market Capitalization $2.

5 billion Revenue (TTM) $1. 3 billion Net Income (TTM) $67. 7 million Company Snapshot Progyny operates as a specialized benefits management platform, providing comprehensive fertility and family-building solutions to employers.

It features a distinctive benefits plan architecture, personalized member support services, and access to a curated network of top-tier fertility specialists, complemented by its Progyny Rx pharmaceutical offering. The company generates revenue through a subscription-based benefits management model where employers contract with Progyny to provide fertility and family-building benefits to their employees, supplemented by revenue from pharmaceutical services and ancillary offerings. Progyny primarily serves mid-to-large employers across the United States seeking to offer comprehensive fertility and family-building benefits as part of their employee benefits packages, addressing the growing demand for specialized reproductive health coverage.

Story Continues Progyny is a market-leading benefits management company with a $2. 5 billion market capitalization, generating $1. 3 billion in TTM revenue with $67.

7 million in net income. The company has established a differentiated competitive position through its integrated platform combining benefits administration, personalized member services, and access to a selective network of fertility specialists, positioning it as a strategic partner for employers seeking to attract and retain talent through comprehensive family-building benefits. What this transaction means for investors COO Cummings' sales were pretty run-of-the-mill transactions.

Some of it covered withholding taxes generated from restricted stock units, and the rest came from structured, pre-planned sales. Investors shouldn't worry too much about these sales -- it wasn't done in reaction to the stock's price or its fundamentals. As for Progyny's stock, its share price has nearly doubled over the last few months after the company reported better-than-expected earnings and guidance in May.

Despite losing one of its largest clients (suspected to be Amazon , though not confirmed), Progyny has rebounded nicely, delivering 1% sales growth in its most recent quarter, even though the customer accounted for 11 percentage points of a growth slowdown. Meanwhile, Progyny's margins have continued to improve, giving management the confidence to repurchase $200 million in shares, lowering its share count by 18% since 2024. Recently, another $200 million repurchase plan was put in place, which represents nearly 10% of its remaining shares.

Progyny is a core holding for me, and I will continue adding to it over time. However, I'll be watching customer concentration and a growing list of competitors very closely to see whether Progyny can gradually build a sustainable moat. Should you buy stock in Progyny right now?

Before you buy stock in Progyny, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the  10 best stocks for investors to buy now… and Progyny wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004...

if you invested $1,000 at the time of our recommendation,  you'd have $371,842 ! * Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,244,783 !

* Now, it's worth noting  Stock Advisor's total average return is 900% — a market-crushing outperformance compared to 207% for the S&P 500.  Don't miss the latest top 10 list, available with  Stock Advisor , and join an investing community built by individual investors for individual investors. See the 10 stocks » *Stock Advisor returns as of July 19, 2026.

Josh Kohn-Lindquist has positions in Progyny. The Motley Fool has positions in and recommends Amazon and Progyny. The Motley Fool has a disclosure policy .